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The aim of this study was to evaluate the prevalence of Helicobacter pylori
genotypes (vacA and cagPAI) directly in gastric biopsy specimens in patients with
gastric diseases in Belarus. Gastric biopsies were collected from 461 patients with
different gastrointestinal disorders: superficial gastritis (287 subjects), atrophy gastritis
(59 subjects), erosive gastritis (47 subjects), duodenal ulcer disease (54 subjects), and
stomach ulcer (14 subjects). PCR-based genotyping was used to detect s1a, s1b, s2,
m1a, m1b, m2, cagM, cagA, and cagT genes. Overall prevalence of vacA s1a allele
was 60.5% followed by m2 (47.1%) and m1a (37.5%). The analysis of data showed
that genotype s1a/m1a was significantly more prevalent in patients with duodenal
ulcer (21.4% vs. 45.1%, OR= 3.0, 95% CI= 1.5–6.1). The cagA gene was found with
a high incidence in most patients with inflammatory diseases of stomach and
duodenum. There was a significant increase in the frequency of cagT in patients
with duodenal ulcer as compared to superficial gastritis. A high cagM prevalence was
found in patients with atrophy gastritis and duodenal ulcer disease. All three island
genes of pathogenicity of cagPAI are more often detected in patients with duodenal
ulcer, which increases the risk of developing duodenal ulcer by 4.5 times.
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Introduction
Helicobacter pylori (HP) is possibly the most widespread human pathogen
that causes of gastritis, peptic ulceration, and gastric cancer. According to World
Health Organization statistics, HP is reported as a class 1 carcinogen in gastric
adenocarcinoma [1].
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However, only a small part of infected people develop disease, and the
disease outcome is influenced by a combination of host, bacterial, and environ-
mental factors [2]. It is important to determine the most prevalent genotypes in a
specific region of human population to find a correlation between putative
virulence genes and clinical outcome. In areas of high HP infection prevalence,
this information may potentially help us to predict the patient’s disease course.
HP is a slow-growing Gram-negative curved or S-shaped rod with a single
tuft of multiple-polar flagella and characteristic terminal bulb. The organism does
not form spores but, under adverse conditions, undergoes transformation from
spiral to coccoid morphology often accompanied by a loss of culturability on
conventional media. The organism is fastidious and cultivation in vitro requires a
microaerophilic environment and complex media.
The core and pan genomes of HP were studied by Cao et al. [3] that
compared 75HP genomes and found an open and diverse core genome with 1,173
conserved protein families and 673 conserved protein domains in theHelicobacter
genus.
Approximately 89% of the predicted open-reading frames are common to
different strains, confirming HP as a single species. A region containing 45% of
HP strain-specific open-reading frames, termed the plasticity zone, is present on
the chromosomes, verifying that some strain variability exists. The plasticity zone
in HP exhibits great variability [4].
According to the literature, HP studies have focused on two groups of
bacterial virulence factors, such as the cag pathogenicity island (cagPAI) and
the vacuolating cytotoxin vacA. The vacA cytotoxin is a well-known HP virulence
factor with multiple cellular effects. Bacterial strains have revealed that the vacA
gene differs in its signal sequence (s1a, s1b, s1c, or s2) and in its mid-region
sequence (m1 or m2). Its virulence function has been implicated in the pathogen-
esis of peptic ulceration and a number of gastroduodenal disorders [5–7].
The cagPAI of HP is a ∼40 kb region of chromosomal DNA that contains
∼27 Cag proteins, whose part of them encodes components of a bacterial type-IV
secretion system (T4SS). One of the most studied putative virulence factors is
the CagA protein, encoded by the cagA gene. Some HP strains contain only
parts of the cagPAI and not the whole set of 27 genes [8]. The combination of
cagPAI genes can also have an effect on the HP virulence and the clinical
outcome.
The aim of this study was to evaluate the prevalence of HP genotypes (vacA
and cagPAI) directly in gastric biopsy specimens in patients with gastric diseases
in Belarus.
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Material and Methods
Gastric biopsies were collected from 461 patients (average age of 42.9 years,
269 women and 192 men) with different gastrointestinal disorders in the medical
center “Nordin” (Minsk, Belarus) from 2013 to 2015. All patients signed an
informed consent form.
The specimens were examined for the presence of HP by polymerase chain
reaction (PCR). Based on endoscopic and histological findings, 287 patients
presented superficial gastritis (SG), 59 had atrophy gastritis (AG), 47 had erosive
gastritis (EG), 54 had duodenal ulcer disease (DU), and 14 patients were
diagnosed to have stomach ulcer (SU).
Total DNA was extracted from frozen gastric biopsy specimens by
DNA-sorbC (Apmlisens, Russia).
HP genotyping
A 267-bp fragment of the 23S rRNA gene ofHPwas amplified using primers
HP-F and HP-R [9].
Gene amplification by PCR was prepared in a volume of 25 μl containing
1 × PCR buffer, 3 mM of MgCl2, 0.2 mM of deoxynucleoside triphosphate, 0.5U
of Taq polymerase, 10 pmol of each primer, 1.5 μl of DNA, and sterile distilled
water. PCR amplifications were performed in an automated thermal cycler
(Thercyc, Russia). All runs included a negative DNA control consisting of PCR
grade water.
PCR-based genotyping was used to detect s1a, s1b, s2, m1a, m1b, m2,
cagM, cagA, and cagT genes (Table I) using previously published primers
[10, 11].
Subsequently, DNA fragments were separated by electrophoresis on 1.2%
agarose gel, stained with ethidium bromide, and visualized under UV transillu-
minator. Standards of 50 or 100 bp (Life Technologies, Lithuania) were used as
molecular size markers.
Statistical analysis
The χ2 test was applied to estimate the statistical differences between disease
and various genotypes. The p value<0.05 was considered as significant statistical
differences.
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Results
Studied population
A total of 461 patients were studied [192 men (41.6%) and 296 women
(58.4%)], aged between 22 and 84 years with mean age of 43.0± 0.7 years.
Analysis showed that 64.9% of patients were HP-infected (41.8% of men vs.
58.2% of women).
The histological data exhibited a significantly higher degree of inflammation
(78%) and neutrophil activity (50.3%) in HP-positive patients (p< 0.05).
The clinical examination shows (Table II) that, among HP-positive, 11%
patients have AG, 57.8% have SG, 10.4% have EG, 17% have DU, and 3.7% have
SU. The analysis shows a significant increase in the number of people with DU
among HP-positive patients; the risk of the disease increases by 10.8 times
(p< 0.05, 95% CI=−3.2 to 44.5).
Figure 1 shows the comparison of the frequency of HP infection between
groups depending on age and clinical outcome.
Table I. Primers used for HP genotyping by PCR
Gene Primer sequence
Size of the amplified
product (bp)
HP F: 5′-AGGTTAAGAGGATGCGTCAGTC-3′ 267
R: 5′-CGCATGATATTCCCATTAGCAGT-3′
s1a F: 5′-GTCAGCATCACACCGCAAC-3′ 190
R: 5′-CTGCTTGAATGCGCCAAAC-3′
s1b F: 5′-AGCGCCATACCGCAAGAG-3′ 187
R: 5′-CTGCTTGAATGCGCCAAAC-3′
s2 F: 5′-GCTAACACGCCAAATGATCC-3′ 199
R: 5′-CTGCTTGAATGCGCCAAAC-3′
m1a F: 5′-GGTCAAAATGCGGTCATGG-3′ 290
R: 5′-CTGTTAGTGCCCGCAGAAAC-3′
m1b F: 5′-GGCCCCAATGCAGTCATGGAT-3′ 295
R: 5′-GCTGTTAGTGCCTAAAGAAGCAT-3′
m2 F: 5′-GGAGCCCCAGGAAACATTG-3′ 352
R: 5′-CATAACTAGCGCCTTGCAC-3′
cagA F: 5′-AATACACCAACGCCTCCAAG-3′ 400
R: 5′-TTGTTGCCGCTTTTGCTCTC-3′
cagM F: 5′-ACAAATACAAAAAAGAAAAAGAGGC-3′ 586
R: 5′-ATTTTTCAACAAGTTAGAAAAAGCC-3′
cagT F: 5′-CCATGTTTATACGCCTGTGT-3′ 301
R: 5′-CATCACCACACCCTTTTGAT-3′
Note: HP: Helicobacter pylori; PCR: polymerase chain reaction; F: forward; R: reverse.
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Among the patients less than 50 years of age, SG dominated (p< 0.01)
regardless of HP status (significantly higher than patients >50 years of age,
p< 0.01).
In the group of HP-negative patients with AG and EG, an increase in the
number of people over the age of 50 years was found. In group with AG in the
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Figure 1. Distribution of HP-positive patients in different clinical outcome groups depending upon
age. SG: superficial gastritis; AG: atrophy gastritis; EG: erosive gastritis; DU: duodenal ulcer; SU:
stomach ulcer. *Significant in comparison with group <50 years, p< 0.05
Table II. The frequency of HP infection between groups depending upon age and clinical diagnosis
Groups of patients
HP detection
Total (%)Negative (%) Positive (%)
Men 41.4 41.8 41.6
Women 58.6 58.2 58.4
Age
<50 years 59.9 69.2 65.9
>50 years 40.1 30.8 34.1
Morphological diagnosis
Atrophy gastritis (AG) 16.0 11.0 12.8
Superficial gastritis (SG) 70.4 57.8 62.3
Erosive gastritis (EG) 9.8 10.4 10.2
Duodenal ulcer disease (DU) 1.9 17.1* 11.7
Stomach ulcer (SU) 1.9 3.7 3.0
Note: HP: Helicobacter pylori.
*Significant in comparison with HP-negative group, p< 0.05.
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presence of HP infection, an increase in the number of patients less than 50 years
of age is observed.
Thus, the presence of HP is a risk factor for developing AG in younger age
people. Among HP-positive patients, a significant increase in the percentage of
people with EG and DU in a group less than 50 years is observed. In the group of
HP-negative patients with gastric ulcer, an increase in the number of individuals
less than 50 years was not detected. In the detection ofHP, the incidence of gastric
ulcer in this group was 45.5%.
Pathogenicity genes detection frequency in HP-positive patients’ gastric biopsies
The presence of the pathogenicity genes was examined in all 299
HP-positive biopsies from patients with gastrointestinal diseases (Figure 2).
The predominant vacA genotype in the biopsies was the s1a (60.5%),
followed by m2 (47.1%) and m1a (37.5%). The HP vacA s1a/m1a genotype was
predominantly detected in our samples (28%). Genotypes s1a/m2 and s2m2 were
almost equally present, i.e., 24% and 21%, respectively. In this study, the rare
s2m1a and s2/m1b genotypes were detected in 4% and 1.3%, respectively.
The cagA gene was observed in 202 of 299 (67.6%) biopsies, and cagT and
cagM detected with frequencies of 47.5% (142/299) and 35.8% (107/299),
respectively. A significant correlation between the simultaneous presence of cagA,
cagM, and cagT genes was found (p< 0.0001).
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Figure 2. Distribution of genotypes for all HP-positive samples
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The most of cagA-positive samples possessed the s1a form of vacA gene
(73.3%), whereas among cagA-negative samples, only 14.8% contained s1a vacA.
The analysis showed that combination of three cagPAI genes (cagA, cagM, and
cag T) was found in 30.4% samples.
Relationship between HP genotypes and clinical outcomes
The genotypes of HP found in patients with different gastrointestinal
diseases are presented in Table III.
Statistical comparative analysis of the frequency of each allele in the
different form of disease revealed an association between allele s1a and the
presence of AG (p< 0.05, OR= 3.7, 95% CI= 1.4–10.0), EG (p< 0.05,
OR= 2.4, 95% CI= 1.0–6.1), and DU (p< 0.02, OR= 3.2, 95% CI= 1.5–7.1).
The vacA s1b genotype was detected only in 12% of 299 patients: 9.1% with AG,
17.3% with SG, 3.2% with EG, and 7.8% with DU.
The association of middle vacA regions with clinical outcomes shows that
m1a allele was more frequently identified in patients with DU (53%). There were
no differences in m1b allele between all clinical groups, whereas m2 was the most
predominant genotype in patients with SG and EG.
Table III. Association of HP genotypes with clinical diagnosis
Allele/gene
Clinical diagnosis
AG [n (%)] SG [n (%)] EG [n (%)] DU [n (%)] SU n (%)]
s1a 26 (78.8)* 86 (49.7) 22 (71)* 39 (76.5)* 8 (72.7)
s1b 3 (9.1) 30 (17.3) 1 (3.2) 4 (7.8) 0
s2 4 (12.1) 57 (33) 8 (25.8) 8 (15.7) 3 (27.3)
m1a 13 (39.4) 58 (33.5) 10 (32.3) 27 (53)* 4 (36.4)
m1b 5 (15.1) 28 (16.2) 5 (16.1) 6 (11.8) 2 (18.2)
m2 15 (45.5) 87 (50.3) 16 (51.6) 18 (35.2) 5 (45.4)
s1a/m1a 12 (36.4) 37 (21.4) 9 (29) 23 (45.1)* 3 (27.3)
s2/m2 3 (9.1) 44 (25.4) 8 (25.8) 6 (11.8) 3 (27.3)
s1a/m2 12 (36.4) 38 (22) 9 (29) 11 (21.6) 2 (18.2)
s2/m1a 0 8 (4.6) 0 0 0
cagM 17 (51.5)* 48 (27.7) 8 (25.8) 30 (58.8)* 4 (36.4)
cagA 25 (75.8)* 96 (55.5) 26 (83.9)* 46 (90.2)* 10 (90.1)*
cagT 17 (51.5) 62 (35.8) 15 (48.4) 41 (80.4)* 7 (63.6)
Gene combination
cagM/cagA/cagT 13 (39.4) 39 (22.5) 8 (25.8) 29 (56.9)* 2 (18.2)
s1a/cagM/cagA/cagT 12 (36.4) 32 (18.5) 8 (25.8) 25 (49) 1 (9.1)
Note: SG: superficial gastritis; AG: atrophy gastritis; EG: erosive gastritis; DU: duodenal ulcer; SU: stomach
ulcer.
*Significant difference in comparison with SG group, p< 0.05.
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Genotype s1a/m1a was significantly found predominantly in patients with
DU (p= 0.002, OR= 3.0, 95% CI= 1.5–6.1). Although in this study, s1a/m1a
alleles were also more prevalent in HP samples in patients with AG (36.4%), but
the results showed no statistical significance.
More than 20% of the SG, EG, and SU patients were infected with s2m2
genotype bacteria. However, no significant correlation was observed between this
virulence marker and disease status.
In this study, the cagA gene was found with a high incidence in most patients
with inflammatory diseases of the stomach and duodenum: 75.8% in cases of AG,
83.9% – EG, 90.2% – DU, and 90.1% in cases of gastric ulcer. Simultaneously,
there was a significant increase in the frequency of cagT in patients with DU as
compared to SG (p< 0.001, OR= 7.3, 95% CI= 3.2–16.8). A high cagM
prevalence was also found in patients with AG and DU diseases.
The analysis of the data showed that in the biopsy samples obtained from
patients with DU, all three island genes of pathogenicity of cagPAI are reliably
more often detected in comparison with SG patients – 56.9% vs. 22.5%, which
increases the risk of developing DU by 4.5 times (OR= 4.5, 95% CI= 2.2–9.2).
The combination s1a/cagM/cagA/cagT was detected in 49% (p= 0.001,
OR= 4.2, 95% CI= 2.1–8.7) and 36.4% (p= 0.05, OR= 2.5, 95% CI= 1.0–6.1)
of patients with PU and AG, respectively.
Discussion
Gastric and systemic immune responses develop within a short period of time
after HP infection. The gastric inflammatory response induced by HP consists of
neutrophils, lymphocytes, plasma cells, dendritic cells, and macrophages, along with
varying degrees of epithelial cell degeneration and injury [12]. Contact between HP
and gastric epithelial cells results in activation of NF-κB, which is followed by
increased interleukin-8 (IL-8) expression [13]. IL-18 is essential for inducing
CD4+CD25+ FOXP3+ regulatory T cell in response to HP, which in turn
restricts excessive effector T-cell activation and promotes infection persistence [14].
After entering the host mucosa stomach, HP utilizes its urease activity to
neutralize the hostile acidic condition at the onset of infection. Then, HP use
flagella-mediated motility to move toward host gastric epithelium cells. Finally,
HP releases several effector proteins/toxins causing host tissue damage [7].
Differences in the prevalence of HP genotypes could play a role in the
incidence diseases. This study analyzed the association between gastric mucosa
pathology and HP genotypes.
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VacA is a key toxin for HP pathogenesis. VacA is bound to cell surface and
initiates a pro-inflammatory response. It modulates T- and B-cell activation and
proliferation, and if the toxin is transported to the mitochondria, it induces
apoptosis [15]. The vacA gene is present in all HP strains and comprises variable
regions (signal – s, middle – m, and intermediate – i).
The vacA signal region encodes the N terminus of the toxin and may
be active (type s1) or encode an N-terminal extension, which blocks activity
(type s2). The vacAmid-region may bind to a wide range of cells, causing toxicity
(type m1) or to a smaller range (type m2) [7]. Genotypic combination of vacA
alleles results in different pathogenicity level as follows: s1am1 produces high
amount of toxin and consequently the most virulent, s1m2 – produces moderate
vacuolating toxins [11].
Conclusions about any association between the presence of HP genotypes
and clinical outcome may not be true because there is a geographic variability of
HP genotypes [16, 17]. It is important to determine the most prevalent genotypes
in a specific region and to confirm whether there is a correlation between putative
virulence genes and diseases. According to the literature, the vacA s1a allele is
found most predominantly in Northern and Eastern European strains, whereas s1b
is prevalent in Latin America [18–20].
It is known that patients with the vacA s1a gene had a significantly more
strong degree of chronic inflammation, whereas those with vacA s2 had signifi-
cantly less activity inflammation [21, 22].
In agreement with other studies, we confirmed that the most determinated
vacA allele is s1a [22–24] and less common is allele m1a. Our findings demon-
strate an association between the presence of the s1a allele and the presence of AG,
EG, and DU. The explanation for these results may be stated that HP strains with
the s1a genotype produce more vacuolating toxin and might contribute to the more
effective development of inflammation.
Atherton et al. [25] demonstrated that m1a alleles are associated with gastric
epithelial injury. Our results also demonstrate an association between the presence
of the m1a allele and presence of DU.
We found that the frequency of the genotype s1a/m1a vacA gene in patients
with chronic SG was 21.4%; it is significantly lower compared with the group of
patients with DU – 45.1% (p< 0.05, OR= 3.0, 95% CI= 1.5–6.1).
The cagPAI is one of the important virulence determinants of HP. The
cagPAI encodes 27–31 proteins and comprises two regions – cagI and cagII. The
cagPAI genes encode a T4SS that forms a structure to translocate the cagA protein
into the gastric epithelial cells. In addition, the cagPAI stimulates the release of
pro-inflammatory cytokines in gastric mucosa, including IL-8 [8].
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In this investigation, the cagA and cagMwere selected to represent cagI, and
cagT was selected to represent cagII.
The primary virulence determinant of HP is CagA oncoprotein, which is
associated with development of severe outcomes of the infection [26]. When
CagA protein is introduced into a host cell, toxic change leads to abnormal
proliferation, motility, and cytoskeletal change in gastric epithelial cells [27].
In European studies of HP strains, the frequency of cagA has shown
variations (72%–81%) and has been higher in southeast European countries
(Bulgaria, Greece, and Turkey) [18, 28, 29]. A high cagA gene frequency
(86%–87%) is observed in East Asia [30, 31]. The results of this study also
showed that the prevalence of cagA is significantly higher among different disease
groups in comparison with SG group (p< 0.05). The highest percentage is
observed in patients with ulcer (90.2%).
The cagT is located at the 3′ end of the cagII region. Studies showed that
strains lacking the cagT gene had a defective “molecular syringe” that is encoded
by the PAI [32], thus reflecting on inability of the type-IV system to eject out the
cagA protein. Our results show that the prevalence of cagT was significantly
different in patients with DUs compared with those with non-ulcer dyspepsia and
it is a better marker than the cagA status for ulcer clinical outcome. Other studies
conducted elsewhere also support our findings; in England, Kauser et al. [19]
found an association between cagT and ulcer development.
We found a significant correlation between the simultaneous presence of
cagPAI genes in the samples studied. It was found that combination cagM/cagA/
cagT is detected more frequently in patients with peptic ulcer than in patients with
chronic gastritis. The data show the significant roles of CagT and CagM in the
T4SS effectivity in HP–host interaction that results in an enhanced ability of the
bacterium to colonize the antral gastric niche.
This study analyzed the relationship between HP genotypes and clinical
data of gastrointestinal diseases. The results presented in this study show that the
HP samples from patients suffering DU had a high expression of s1a/m1a
genotype (45.1%). We conclude that genotyping of HP (cagPAI) may be useful
in clinical practice for identifying patients with a high risk of developing gastric
diseases.
We think that the prevalence of virulence-associated HP genotypes
has clinical implications for our understanding of the pathogenesis of infection
and related gastric disorders. In future studies, it would be of interest to
evaluate the influence of other pathogenicity genes in helicobacteriosis clinical
outcome.
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